G6PD Deficiency: The Most Common Enzyme Deficiency Worldwide

Photo Credit: CDC/ Dr. Gilda L. Jones

Introduction

Glucose-6-phosphate dehydrogenase (G6PD) deficiency affects more than 400 million individuals globally, making it the most common enzymopathy in humans and one of the most prevalent genetic disorders worldwide.¹ Yet despite this remarkable prevalence, G6PD deficiency remains underdiagnosed and poorly understood in many populations. For researchers, this condition offers unique opportunities to investigate oxidative stress mechanisms, pharmacogenomics, and the intersection of genetic protection and disease susceptibility.

The Molecular Basis: When Antioxidant Defense Fails

G6PD is the rate-limiting enzyme in the pentose phosphate pathway, the primary source of NADPH in red blood cells. NADPH is essential for maintaining reduced glutathione, which protects cells against oxidative damage. When G6PD activity is deficient, red blood cells become vulnerable to oxidative stress, leading to hemolysis when exposed to specific triggers.²

This simplified explanation belies remarkable complexity. More than 200 G6PD variants have been identified, each with different levels of residual enzyme activity, stability, and clinical consequences. The WHO classification system categorizes variants from Class I (severe deficiency with chronic hemolytic anemia) to Class V (increased enzyme activity), with most clinically significant variants falling into Classes II and III.³

Geographic Distribution and Evolutionary Selection

G6PD deficiency shows striking geographic patterns, with highest prevalence in:

• Sub-Saharan Africa (5–25% of males in some regions)
• Mediterranean basin (3–30% prevalence)
• Middle East and Southeast Asia (3–15%)
• Papua New Guinea and Oceania (up to 50% in some populations)

This distribution overlaps closely with historical malaria endemicity, reflecting positive selection for G6PD deficiency alleles that confer partial protection against severe malaria — a classic example of balanced polymorphism where heterozygote advantage maintains disease alleles in populations.⁴

For biospecimen research, this geographic and ethnic diversity means that study populations must be carefully characterized. A G6PD-deficient individual from West Africa likely carries the A- variant (G202A/A376G), differing from a Mediterranean patient with the more severe Mediterranean variant (C563T), with distinct clinical implications.

Clinical Manifestations: From Silent Carriers to Acute Crises

The clinical spectrum of G6PD deficiency ranges from lifelong asymptomatic status to severe, life-threatening hemolytic crises, depending on variant severity and trigger exposure.

Acute Hemolytic Anemia

The most common clinical manifestation is acute hemolytic anemia triggered by oxidative stressors:

Pharmacological triggers:

• Antimalarials (primaquine, tafenoquine)
• Sulfonamides and sulfones (cotrimoxazole, dapsone)
• Rasburicase (urate oxidase used in tumor lysis syndrome)
• Certain analgesics and antipyretics

Infections: Bacterial and viral infections can trigger hemolysis through oxidative stress from immune response and pathogen-derived factors.

Fava beans: Consumption of fava beans (favism) can cause severe acute hemolysis in individuals with certain variants, particularly Mediterranean and some Asian variants.

Other triggers: Mothballs (naphthalene), henna, diabetic ketoacidosis.

When hemolysis occurs, patients may develop acute anemia, jaundice, dark urine (hemoglobinuria), and potentially complications including acute kidney injury. Laboratory findings typically include reduced hemoglobin, elevated lactate dehydrogenase and indirect bilirubin, low haptoglobin, and characteristic blood smear findings (Heinz bodies, bite cells).⁵

Neonatal Hyperbilirubinemia

G6PD deficiency is a significant cause of neonatal jaundice, particularly in populations with high prevalence. Severe neonatal hyperbilirubinemia can lead to kernicterus and permanent neurological damage if not recognized and treated promptly. Many countries with high G6PD deficiency prevalence have implemented newborn screening programs.⁶

Chronic Hemolytic Anemia

Class I variants can cause chronic non-spherocytic hemolytic anemia even without specific trigger exposure. Severely affected individuals may require ongoing management including folic acid supplementation, avoidance of oxidative stressors, and sometimes transfusion support.

Diagnostic Approaches: Detecting Deficiency Across the Spectrum

Diagnosis of confirmed G6PD deficiency requires enzyme activity measurement, though screening tests and genetic analysis play complementary roles.

Enzyme Activity Assays

Quantitative spectrophotometric assay: The gold standard measures G6PD activity under standardized conditions, typically reported per gram of hemoglobin or per red blood cell. Activity <30% of normal indicates significant deficiency, though cutoffs vary by assay and population.

Fluorescent spot test: A rapid, semi-quantitative screening method detecting NADPH generation under UV light. While useful for screening, positive results require confirmatory quantitative testing.⁷

Important diagnostic considerations:

• Recent transfusion can mask deficiency (donor RBCs)
• Reticulocytosis after a hemolytic episode can cause false-negative results (young RBCs have higher activity)
• Heterozygous females may show mosaic patterns due to X-inactivation, complicating diagnosis

Genetic Testing

DNA sequencing can identify specific G6PD variants, providing definitive diagnosis independent of enzyme activity fluctuations. Genetic testing is particularly valuable for:

• Confirming diagnosis in ambiguous cases
• Identifying specific variants for research studies
• Prenatal diagnosis in families with severe variants
• Population screening programs
• Pharmacogenomic applications (determining malaria drug safety)

For biospecimen research, specimens with both enzyme activity measurements and genetic variant characterization provide maximum value, enabling genotype-phenotype correlation studies and functional analyses of specific variants.

Emerging Biomarkers: Beyond Enzyme Activity

While enzyme activity measurement remains central to diagnosis, researchers are identifying additional biomarkers that may enhance detection, particularly of subclinical hemolysis.

Circulating microRNAs

A study published in 2024 identified circulating microRNAs — particularly miR-451a, miR-16, and miR-155 — as potential biomarkers for detecting subclinical hemolysis in G6PD deficiency. Using multidimensional analysis of these miRNAs together could differentiate G6PD-deficient individuals from controls even during non-acute phases when standard hemolysis indices appear normal.⁸

Implications include:

• Earlier detection of hemolysis before clinical manifestations
• Monitoring oxidative stress burden across contexts
• Risk stratification for individuals with borderline activity
• Therapeutic monitoring for antioxidant or protective interventions

Validating microRNA biomarkers across diverse ancestries, variants, and trigger contexts remains a research priority, requiring well-characterized biospecimens from patients with confirmed deficiency, documented variants, and detailed phenotypes.

G6PD Activity as a Biomarker for Other Conditions

G6PD activity itself is also being explored as a biomarker outside primary deficiency. Research suggests decreased G6PD activity may be associated with diabetes mellitus and oxidative stress burden, potentially correlating with glycemic control.⁹ These relationships require comparative studies across cohorts with G6PD deficiency, diabetes, both conditions, and neither.

Management and Prevention: Knowledge Enables Avoidance

No specific curative treatment for G6PD deficiency exists — management centers on avoiding triggers and providing supportive care during hemolytic episodes.

Primary Prevention Through Education

• Accurate diagnosis and communication of G6PD status
• Clear guidance on medications to avoid
• Awareness of non-pharmacological triggers (fava beans, naphthalene)
• Instructions to inform clinicians before starting new medications

Management of Acute Hemolysis

• Discontinue the triggering agent immediately
• Supportive care and hydration
• Transfusion support for severe anemia
• Monitoring for acute kidney injury related to hemoglobinuria
• Folic acid supplementation during recovery (increased erythropoiesis demand)

Public Health Interventions

• Newborn screening in high-prevalence regions
• Pre-prescription testing for high-risk medications (e.g., primaquine)
• Pharmacovigilance programs in G6PD-deficient populations
• Point-of-care diagnostics for resource-limited settings

Research Priorities and Opportunities

Can We Predict Hemolytic Risk More Precisely?

Not all G6PD-deficient individuals experience hemolysis with every trigger exposure. Influencing factors likely include:

• Specific variant and residual enzyme activity level
• Trigger dose and duration
• Co-existing conditions affecting oxidative stress
• Genetic modifiers in related pathways

Biospecimens from individuals with known trigger exposures and documented outcomes (hemolysis vs. no hemolysis) can support predictive biomarker development and risk modeling.

What Are the Long-Term Consequences of Subclinical Hemolysis?

Some individuals demonstrate evidence of mild, chronic hemolysis even without acute crises. Whether this contributes to long-term cardiovascular or other outcomes remains an important open question, with emerging signals warranting additional investigation.¹⁰

Can Therapeutic Interventions Reduce Oxidative Stress?

While avoidance remains primary, mechanistically targeted interventions (e.g., antioxidant support) are of interest, though no proven benefit is established. Carefully designed studies could identify subgroups who benefit from supportive interventions.¹¹

How Can We Safely Expand Access to Life-Saving Medications?

Antimalarials such as primaquine and tafenoquine are important tools for malaria elimination but pose hemolytic risks in G6PD deficiency. Research priorities include:

• Safer dosing regimens minimizing hemolysis
• Genotype- or severity-guided dosing
• Prophylactic strategies enabling use when necessary
• Alternative therapies with improved safety profiles

Biospecimen Requirements for G6PD Research

Rigorous G6PD deficiency research depends on specimens with comprehensive clinical annotation and appropriate sample handling.

Essential Clinical Documentation

Diagnostic confirmation:

• Quantitative G6PD enzyme activity measurement
• Specific genetic variant identification when available
• WHO classification (Class I–V)
• Method and timing of testing (avoid testing during acute hemolysis or shortly after transfusion)

Phenotypic characterization:

• History of hemolytic episodes (number, triggers, severity)
• Neonatal jaundice history
• Baseline hemoglobin and hemolysis markers
• Comorbid conditions (e.g., diabetes, cardiovascular disease)

Ancestry and geographic origin:

• Important given geographic clustering of variants
• Supports variant inference when sequencing is unavailable

Appropriate Sample Types

Different research applications require different specimen formats. For many hematology and oxidative stress investigations, paired blood fractions enable integrated multi-omic and clinical correlation studies:

• Whole blood: Enzyme activity measurement workflows, DNA extraction for variant identification, and cellular assays using standardized protocols. See human whole blood.
• Plasma: microRNA profiling, inflammatory marker measurement, and proteomics. See human plasma (or human bulk plasma for higher-volume study needs).
• Serum: biochemical hemolysis markers and metabolomics. See human serum.
• PBMCs: gene expression studies and cellular stress-response investigations. See human PBMCs.

At SanguineBio, our hematological disease biospecimens include G6PD deficiency samples with documented enzyme activity, variant characterization when available, and clinical annotation from patients across the United States representing diverse ancestries and geographic origins.

Global Health Implications

G6PD deficiency sits at the intersection of genetics, pharmacology, infectious disease, and global health. High prevalence in malaria-endemic regions complicates malaria elimination efforts that rely on drugs with hemolytic potential. As a pharmacogenomic factor, it influences medication safety across multiple therapeutic areas. As a balanced polymorphism, it offers insights into evolutionary medicine and host-pathogen interactions.

For global health researchers, designing studies that account for variant diversity and differential risk is essential. Biospecimen repositories supporting this work must include samples from populations that are frequently underrepresented in biomedical research despite bearing the highest disease burden.

Conclusion

G6PD deficiency exemplifies how a single enzyme defect can create diverse clinical outcomes — from silent carrier status to life-threatening hemolysis — depending on genetic variant, environmental exposures, and host factors. As the most common enzymopathy worldwide, it affects hundreds of millions and intersects with major public health programs ranging from malaria control to neonatal care.

Research opportunities include validating emerging biomarkers such as circulating microRNAs, clarifying the consequences of subclinical hemolysis, developing safer access pathways to essential medications, and understanding how genetic protection against malaria shapes disease risk. Progress depends on access to well-characterized biospecimens from diverse populations with confirmed diagnoses and robust clinical and molecular annotation.

Explore our G6PD deficiency biospecimens or request a custom collection for global health or pharmacogenomics research.

---

References (AMA Style)

1. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009;42(3):267-278. doi:10.1016/j.bcmd.2008.12.005
2. Luzzatto L, Nannelli C, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Hematol Oncol Clin North Am. 2016;30(2):373-393. doi:10.1016/j.hoc.2015.11.006
3. World Health Organization Working Group. Glucose-6-phosphate dehydrogenase deficiency. Bull World Health Organ. 1989;67(6):601-611.
4. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371(9606):64-74. doi:10.1016/S0140-6736(08)60073-2
5. Frank JE. Diagnosis and management of G6PD deficiency. Am Fam Physician. 2005;72(7):1277-1282.
6. Mohamed GS, Lemine SM, Cheibetta S, Mohamed A. Neonatal screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency in Mauritania. Pan Afr Med J. 2018;30:224. doi:10.11604/pamj.2018.30.224.15805
7. Roper D, Layton M, Rees D, et al. Laboratory diagnosis of G6PD deficiency. A British Society for Haematology Guideline. Br J Haematol. 2020;189(1):24-38. doi:10.1111/bjh.16366
8. Jittikoon J, Sanpakit K, Buaban A, et al. Serum microRNAs as new biomarkers for detecting subclinical hemolysis in G6PD deficiency. Sci Rep. 2024;14(1):16547. doi:10.1038/s41598-024-67394-8
9. Wan GH, Tsai SC, Chiu DT. Decreased blood activity of glucose-6-phosphate dehydrogenase associates with increased risk for diabetes mellitus. Endocrine. 2002;19(2):191-195. doi:10.1385/ENDO:19:2:191
10. Chonat S, Quarmyne MO. Diagnosis and management of glucose-6-phosphate dehydrogenase deficiency. Pediatr Ann. 2020;49(3):e135-e141. doi:10.3928/19382359-20200214-01
11. Dern RJ, Beutler E, Alving AS. The hemolytic effect of primaquine. II. The natural course of the hemolytic anemia and the mechanism of its self-limited character. J Lab Clin Med. 1954;44(2):171-176.